Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (38)

II-01Bram Agema

Improving the tolerability of osimertinib by identifying its toxic limit

Wednesday 15:10-16:40

II-02Doaa Ahmed Mohamed

Development of a physiologically based pharmacokinetic model for intratumoral biodistribution of magnetic iron oxide nanoparticles

Wednesday 15:10-16:40

II-06Claire Brillac

Selection of isatuximab dosing regimen in pediatric patients with leukemia using population PK and PBPK modeling approaches

Wednesday 15:10-16:40

II-07René Bruno

Comparison of two-stage and joint TGI-OS modelling using data from six clinical studies in metastatic non-small cell lung cancer patients

Wednesday 15:10-16:40

II-08Aurore CARROT

A joint K-PD model with the tumor size changes and CA-125 kinetics in patients with advanced ovarian cancer (AOC): analysis of the phase II BOLD study.

Wednesday 15:10-16:40

II-09Marc Cerou

Semi-mechanistic pharmacokinetic-pharmacodynamic modeling of tumor size dynamics in advanced breast cancer patients treated with single-agent amcenestrant

Wednesday 15:10-16:40

II-11S. Y. Amy Cheung

Exposure-Response Analysis of Tovorafenib (DAY101) Relating Objective Response to Exposure, Patient- and Disease Characteristics

Wednesday 15:10-16:40

II-13Christian Hove Claussen

Modeling Mouse Xenograft Tumor Growth Inhibition to Optimize Cycles in Oncology

Wednesday 15:10-16:40

II-14David Damoiseaux

Physiologically based pharmacokinetic model to predict chemotherapy exposure in infants through breastfeeding: paclitaxel as an example

Wednesday 15:10-16:40

II-15Liu Dan

Population pharmacokinetics of selpercatinib in patients with an advanced solid tumor, including RET fusion-positive NSCLC, RET-mutant MTC, and other tumors with increased RET activity

Wednesday 15:10-16:40

II-16Lekshmi Dharmarajan

Preclinical pharmacokinetics and target occupancy of JDQ443, a covalent inhibitor targeting KRAS G12C

Wednesday 15:10-16:40

II-18Yin Edwards

Exposure-safety analysis of Tovorafenib (DAY101), an investigational oral pan-RAF kinase inhibitor, in oncology patients with solid tumors

Wednesday 15:10-16:40

II-23Ana-Marija Grisic

Model-informed noninferiority of cetuximab biweekly to weekly dosing regimen in metastatic colorectal cancer

Wednesday 15:10-16:40

II-27Heeyoon Jung

rhIL-7-hyFc dose optimization for chemotherapy-induced lymphopenia using FcRn mediated IgG disposition model

Wednesday 15:10-16:40

II-31Marie Lambert

A population approach to compare the impact of two amino acid solutions on 177Lu-Dotatate pharmacokinetics in patients with gastroenteropancreatic neuroendocrine tumors

Wednesday 15:10-16:40

II-32Félicien Le Louedec

Non-linear mixed-effects modeling to evaluate the pre-analytical stability of uracilemia in the context of dihydropyrimidine dehydrogenase deficiency testing.

Wednesday 15:10-16:40

II-33Xia Li

Population Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Wednesday 15:10-16:40

II-34Yu-wei Lin

Utilizing model informed drug development to support study design for Tovorafenib (DAY101), a novel, type II, pan RAF kinase inhibitor: a focus on longitudinal safety markers

Wednesday 15:10-16:40

II-35Han Liu

Learning dose-response relationship via PK-TS-multistate clinical endpoints modeling framework: application to bintrafusp alfa in second-line non-small cell lung cancer patients

Wednesday 15:10-16:40

II-36Rubin Lubomirov

Population pharmacokinetic-based, two-stage approach to assess the impact of genetic variants on lurbinectedin exposure in patients with advanced cancer

Wednesday 15:10-16:40

II-37Corinna Maier

Semi-Mechanistic Model to Aid Clinical Understanding of Myelodysplastic Syndromes

Wednesday 15:10-16:40

II-38Yomna Nassar

Cachexia-associated anticancer drug toxicity is minimally mediated by alteration of drug’s pharmacokinetics: Erlotinib as case study

Wednesday 15:10-16:40

II-39Janine Nijhuis

The comparison of pharmacoeconomic and pharmacometric modelling to improve cost-effectiveness assessment of sunitinib in GIST.

Wednesday 15:10-16:40

II-40Qing Xi Ooi

Rituximab PK and PD evaluation based on a study in diffuse large B-cell lymphoma: influence of tumor size on PK and assessment of PK similarity

Wednesday 15:10-16:40

II-41Antoine Pitoy

Joint modeling of longitudinal and time-to-event data for earlier estimation of the primary endpoint in oncology clinical trials: A retrospective analysis of the ICARIA-MM clinical trial

Wednesday 15:10-16:40

II-42Clémence Pouzin

Modelling approaches to support tusamitamab ravtansine (DM4 anti-CEACAM5 antibody-drug conjugate) drug development.

Wednesday 15:10-16:40

II-44Bhaskar Rege

Use of Quantitative System Pharmacology (QSP) Modeling to Optimize Dosing Frequency and Interval for Nemvaleukin Alfa (Nemvaleukin), an Investigational Cancer Immunotherapy

Wednesday 15:10-16:40

II-45Elisabeth Rouits

Exposure-response of different dosing schedules of naratuximab emtansine in combination with rituximab in Non Hodgkin’s lymphoma

Wednesday 15:10-16:40

II-46Javier Sanchez Fernandez

Preclinical in vivo data integrated in a modeling network informs a refined clinical strategy for a CD3 T-Cell bispecific in combination with anti-PD-L1

Wednesday 15:10-16:40

II-47Aymara Sancho

Characterizing the interplay between biological factors and cell growth in unperturbed tumor growth dynamics

Wednesday 15:10-16:40

II-48Celine Sarr

A framework for prediction of progression free survival based on modelling of sub-endpoints

Wednesday 15:10-16:40

II-51Stephan Schaller

A PB-QSP platform model for T cell-dependent bispecific antibodies

Wednesday 15:10-16:40

II-53Hinke Huisman-Siebinga

A Population Pharmacokinetic Model Using Imaging Data to Assess Variability in Pharmacokinetics of 177Lu-PSMA-617 in Low Volume Metastatic Prostate Cancer Patients

Wednesday 15:10-16:40

II-54Zhiyuan Tan

Population Pharmacokinetics of cabozantinib in adult metastatic renal cell carcinoma patients: evaluation of real-world data

Wednesday 15:10-16:40

II-55David Ternant

Influence of immunization on the pharmacokinetics of monoclonal antibodies : anti-drug antibody-mediated drug disposition (ADAMDD) of rituximab in mice

Wednesday 15:10-16:40

II-57Elena Tosca

A clinical trial simulator to predict the effect of an adaptive dosing regimen of an investigated compound on platelets, white blood cells and haematocrit in patients with Polycythemia Vera.

Wednesday 15:10-16:40

II-59Maarten Van Eijk

Optimizing the value of preclinical data for the design of first-in-human clinical studies with oral cabazitaxel through population pharmacokinetic modelling

Wednesday 15:10-16:40

II-63Anyue Yin

Quantitative modelling of exposure-tumor dynamics relationship and development of drug resistance in non-small cell lung cancer patients treated with erlotinib

Wednesday 15:10-16:40